Athira pharma reports full year 2023 financial results and pipeline and business updates

Enrollment completed in phase 2/3 lift-ad clinical trial of fosgonimeton as a potential treatment for mild-to-moderate alzheimer's disease; topline data expected in second half of 2024  on track to initiate first-in-human studies of ath-1105 for the treatment of amyotrophic lateral sclerosis in first half of 2024 strong balance sheet to support innovative pipeline through key inflection points bothell, wash., feb. 22, 2024 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended december 31, 2023, and reviewed recent pipeline and business updates.
ATHA Ratings Summary
ATHA Quant Ranking